Griffin et al. found that targeting SETDB1 using CRISPR‐Cas9 in mouse models enhanced sensitivity to immune checkpoint therapies, with a marked decrease in tumor growth and activation of immune responses.34 Here, SETDB1 is linked to neoplasm.